A 1 % 14C-SL-1010 solution (3mg/kg) was administered repeatedly into the cavitas articulare of left rabbit knee at 4 day intervals for a total of 7 times.
Summary A 1 % 14C-SL-1010 solution (3mg/kg) was administered repeatedly into the cavitas articulare of left rabbit knee at 4 day intervals for a total of 7 times. 1. Residual radioactivity in synovial fluid was approximately 60% of each dose at 24hrs after the 4th and 7th administrations and was comparable to that observed after the first administration.
The clearance of radioactivity from synovial fluid observed after the 7th administration was comparable to a simulated curve projected from results for the first administration study group, and no accumulation was observed as a result of repeated administra tion.
2. Plasma levels of radioactivity reached the steady state following the 3rd administration and gradually decreased from 5 days after the 7th admi nistration with an elimination half-life of 106. Ohrs. The observed plasma pro file of radioactivity was similar to that simulated from results of the single dose study.
3. The primary route of excretion was the expired air. The cumulative excretion of radioactivity in expired air reached the steady state after the 6th administration and reached 81.5% of the total dose at 14 days after the 7th administration.
The cumulative excretion of radioactivity in urine and feces were 3.3% and 2.9%, respectively. These results were similar to those obser ved in the single dose study.
4. The levels of radioactivity in various tissues surrounding the dosing side of the knee joint gradually increased with repeated administration. At 24hrs after the 4th administration, the level had risen to 0. 9-2. 8 times higher levels of that at 24hrs following the first administration, and the peak concentration observed after the 7th administration was 1.4-3.2 times higher than the level at 24hrs following the first administration.
The level of radioactivity was hig hest in the synovial tissue and was followed in order of decreasing radioac tivity by the infrapatellar fat pad, meniscus, patellar ligament, cartilage and patella.
5. The level of radioactivity in the principal tissues beyond the knee joint tended to increase gradually with repeated administration , reaching a peak at 24hrs following the 7th administration.
The peak values for liver, lung, kidney, spleen, Harderian gland, adrenal gland and heart were 2.6-13.6 ti mes higher than the levels at 24hrs after the first administration.Introduction SL-1010 is a highly purified, high molecular weight sodium hyaluronate synthesized via Streptococcus zooepidemicus in Shiseido Co., Ltd.'). This compound is currently under development as a drug for the treatment of osteoarthritis and periarthritis scapulohume ralis.
The pharmacokinetic study of SL-1010 (distribution, metabolism and excretion) was reported in a preceding paper presenting the results of a single intra-articular adminis tration of 14C-labeled SL-1010 (14C-SL-1010) into the rabbit knee 2).
Prior to the present study, a preliminary study was conducted to determine the dosing schedule using 14C-SL-1010, and in the present study, the pharmacokinetics of SL-1010 after repeated administration was investigated. 
Experimental animals
Male Japanese albino rabbits (body weight 2-3kg, Sankyo Labo Service Co., Japan) were fed pellet feed (CR-3, Clea Japan Inc., Japan) and tap water ad libitum. After acclimation to a temperature of 22±1 C and a humidity of 60±10%, animals were sub mitted to the study in groups of three.
Dosage and method of administration
After removing hair at the knee joint, the animals were administered 3 mg/kg of a 1 % 14C-SL-1010 solution into the cavitas articulare of the left knee as described in the preceding paper 2). A total of 7 administrations were performed at 4 day intervals. Then, 1 ml of physiological saline was injected into the cavitas articulare and the synovial fluid was collected after bending the knee 20 times. Sampling points were at 24hrs and 2, 3 and 4 days after the first adminis tration, 24hrs after the 4th administration and 2hrs, 24hrs, 6 and 14 days after the 7th administration.
Measurement of radioactive concentration in blood and plasma
Following the administration of 14C-SL-1010, a 500,ul of blood sample was collected from the auricular vein according to the time schedule. Sampling points were set at 24
hrs after the first administration to 14 days after the 7th administration, with 24hr in tervals. From the blood sample obtained, 200pl was dried on ashless filter paper (Toyo Roshi, Inc., Japan), and used for the measurement. After conventional centrifugation of the remaining blood sample, plasma was obtained and used for the measurement.
6. Measurement of excretion of radioactivity in expired air, urine and feces Animals were housed in metabolic cages after administration of 14C-SL-1010. The natu rally-excreted urine and feces were collected and used for radioactive measurement. Ex pired air was absorbed as 14CO, into an absorbent containing primarily monoethanola mine, and measured for radioactivity. Sampling points were set at 24hrs after the first administration through 14 days after the 7th administration, at 24hr intervals.
Measurement of radioactive concentration in tissues
Following the administration of 14C-SL-1010, animals were killed by exsanguination from the posterior aorta under ether anesthesia. After synovial fluid was obtained as described above, synovial tissue was obtained as described in the previous report 3), fol lowed by the patellar ligament, meniscus, articular cartilage, patella, infrapatellar fat pad, femoral muscle, thigh bone and femoral bone marrow. In respect to systemic organs, the Harderian gland, heart, lung, liver, spleen, kidney and adrenal gland were collected and measured for wet weight. All of the light organs and part of the others were homogenized for measurement of radioactivity. Sampling times were 24hrs after the first and 4th administrations and 2hrs, 24hrs, 6 and 14 days after the 7th adminis tration.
Measurement of radioactivity
Blood and fecal samples were prepared by combustion in an automatic combustion system (Aloka ACS-112). Toluene scintillator was added to the absorbed expired air.
Other samples were solubilized using an alkaline solubilizing agent (primarily potassium Blood and plasma : In a single dose study, the levels of radioactivity in blood and plasma were measured untill 9 days after administration. On and after the last sampling time, those levels were calculated from the slope of elimination phase using the least squares method with extrapolating to 14 days. Based on these results, the simulation curves of 7 repeated administration at 4 day intervals were calculated by overlying prim ciple. The maximum concentration (Cmax) and its time of occurrence (Tmax) were read directly from the concentration-time data. Apparent half-life (T1/2) was estimated using the least-squares method based on the concentration-time data. The area under the con centration-time curve (AUC) was calculated by trapezoidal rule. were approximately 60% of each dosage, and were comparable to that at 24hrs after the first administration. In addition, the profile of elimination of radioactivity from synovial fluid observed after the 7th administration was similar to that of the simulated curve, and no accumulation in the cavitas articulare was observed. In those points where there is no indication of S.D., it is included within the symbol. Arrows mark the dosings. The radioactivity in the carcass was 8.9±-1.0% of the total dose at 14 days after the 7th administration.
Blood and plasma concentrations
(355) Table I shows the levels of radioactivity in tissues at 24hrs after the first and 4th ad ministration, and at 2hrs, 24hrs, 6 and 14 days after the 7th administration.
The levels of radioactivity in various tissues of the dosing side of the knee joint gradu ally increased with repeated administrations. At 24hrs after the 4th administration, the level had risen to 0. 9-2. 8 times higher levels of that at 24hrs following the first adminis tration, and, in addition, the peak concentration observed after the 7th administration was 1.4-3.2 times higher than the level at 24hrs following the first administration. The level of radioactivity was highest in the synovial tissue and was followed in order of de creasing radioactivity by the infrapatellar fat pad, meniscus, patellar ligament, cartilage and patella. At 14 days after the 7th administration, these radioactive concentrations were decreased to a level lower than that observed at 24hrs after the first administra tion. On the other hand, tissues of the non-dosing side of the knee joint showed extre mely low radioactive concentrations compared with those of the dosing site.
The levels of radioactivity in the systemic organs beyond knee joint also showed a tendency to increase gradually with repeated administrations, reaching a peak at 2 or 24 hrs after the 7th administration.
The peak values for liver, lung, kidney, spleen, Har derian gland, adrenal gland and heart were 2.6-13.5 times higher than the levels at 24 hrs after the first administration. By 14 days after the 7th administration, the concentra tions had decreased to 10-60% of those at peak. 
Discussion
A study of sodium hyaluronate after repeated intra-articular administration has been reported by Sakamoto et a14~. The dosing schedule was a combination of 3 and 4 day in tervals, and day 21 was the final dosing day. Previous to the present study, a prelimi nary study was conducted to evaluate the pharmacokinetics of sodium hyaluronate after a single intra-articular administration at the doses of 3mg/kg and 6mg/kg (3mg/kg for each knee joint). The results showed increases in Cmax and AUCo-_ proportionally, but no difference was observed in Tmax and T1/2 (Table II ) . The excretion of radioactivity in expired air, urine and feces were 75, 3 and 2%, respectively, with no difference observed between the two doses. Moreover, the residual radioactivity in synovial fluid after intra articular administration at the dose of 3mg/kg showed a similar profile to that of lmg/ kg reported in the preceding study'). The elimination profile of radioactivity from syno vial fluid after administration of 3mg/kg was closely fitted by an equation of first order.
T1/2 was 30hrs, and almost no residual radioactivity in synovial fluid was observed at 7 days after administration. Based on these results, a dosing schedule with 3mg/kg deli vered at 4 day intervals was selected. On the other hand, five dosings at 1 week intervals are considered likely in the clinical use of SL-1010. Accordingly, 7 repeated administra tions were chosen in the present study to cover the dosing period expected for clinical use.
Residual radioactivity observed in synovial fluid at 24hrs after the 4th and 7th adminis tration were comparable to that observed at 24hrs after the first administration. The radioactive clearance from the cavitas articulare observed after the 7th administration was also comparable with the simulated curve. It was therefore confirmed that there was no residual accumulation observed as a result of repeated administration.
In the cavitas articulare, the tissues contacting directly to synovial fluid such as syno vial tissue, meniscus, and cartilage showed a gradual increase with repeated adminis trations. However, the peak observed following the 7th administration was at most twice that of the first administration, and the elimination observed was almost comparable to that for single dosing reported in the preceding paper2~. Thus, it is considered that there is no accumulation as a result of repeated administration. According to the preceding paper 2), intra-articularly administered 14C-SL-1010 has been reported not to be metabo lized in the cavitas articulare, but rather metabolized primarily in lumb-iliac and popli teal lymph nodes following a molecular weight-related transmigration to the lymph nodes, and is then distributed to the systemic circulation in the form of the low molecular wei ght metabolite. These results suggest that the synovial tissue play an important role in molecular weight-related transmigration from the cavitas articulare to lymph nodes.
The levels of radioactivity in blood and plasma were slightly lower than the corre sponding simulated values during the period of repeated administration. However, this phenomenon reversed on and after 6 or 7 days after the last administration. With regard to radioactivity in plasma and blood cells during and after repeated administration, the amount of 14C-hyaluronic acid was found to be as low as 2.1% or less, and 55.9-93.1%
was present in the plasma and blood cells protein fractions5). No difference was observed from the preceding single dose study2). On the basis of these results, it is concluded that there is no accumulation of 14C-hyaluronic acid in blood as a result of repeated adminis tration.
The level of radioactivity in the principal tissues beyond the knee joint tended to in crease gradually with repeated administration, reaching a peak at 24hrs following the 7th administration.
At peak value, a pattern of distribution similar to that in the preceding single dose study2) was noted. The levels of radioactivity observed in the principal tissues at 24hrs after the 7th administration were 2.6-13.5 times higher than the levels at 24hrs
after the first administration. In respect to radioactive compounds in the liver, kidney and spleen, as low as 2.9% or less of the radioactivity was delivered from 14C-hyluronic acid while 49.1-78.7% was obtained from the protein fraction 5), in agreement with the result obtained from the analysis of protein fraction in liver in the preceding single dose study'). These results indicate that the radioactivity observed in major organs was mainly derived from biomolecules such as protein incorporating degraded 14C-hyaluronate and there is no accumulation resulting from repeated administration of 14C-hyaluronate.
The primary route of excretion observed with repeated administration was expired air.
Total excretions in expired air, urine and feces were 81. 5, 3. 3 and 2. 9%, respectively.
These proportions of excretion were similar to those obtained in the preliminary single dose study. The radioactivity in the carcass was 8. 9% of the total dose at 14 days after the 7th administration, it seems likely that the radioactivity in the carcass was mainly derived from biomolecules such as protein incorporating degraded 14C-hyaluronate.
Thus, no accumulation resulting from repeated intra-articular administration of SL 1010 to rabbits was observed in synovial fluid, blood, plasma, tissues of knee joint or principal organs, and no difference was observed in the excretion profile for expired air, urine and feces compared with the single dose study. We therefore conclude that repeated administration of this drug has no influence on its metabolic fate.
